Scilex Pharmaceuticals is an emerging pharmaceutical company focused on acquiring and commercializing late-stage prescription products.
Scilex Holding Company has raised $20.3M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in November 2025.
Scilex Holding Company's investors include Frazier Healthcare Partners, Yorkville Advisors, Perigrove, Graf Holdings.
Scilex Holding Company is headquartered in Palo Alto, United States.
Scilex Pharmaceuticals is an emerging pharmaceutical company focused on acquiring and commercializing late-stage prescription products.
Scilex Holding Company is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Scilex Holding Company — Funding & Investors." VCBacked, November 24, 2025, https://www.vcbacked.co/company/scilex-holding-company. Accessed November 19, 2026.
VCBacked. (2025). Scilex Holding Company — Funding & Investors. Retrieved November 19, 2026, from https://www.vcbacked.co/company/scilex-holding-company
{{cite web |title=Scilex Holding Company — Funding & Investors |url=https://www.vcbacked.co/company/scilex-holding-company |website=VCBacked |access-date=November 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Scilex Holding Company? Request a listing update